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The objectives were to determine the prevalence of group B streptococcus (GBS) and to characterize antibiotic resistance patterns.
All pregnant women presenting to the triage units at two urban hospitals during three intervals from 2001 to 2004 were included.
Eachintervallastedapproximatelyfourweeks.Swabswereinoculatedintoselectivebrothandculturedontrypticsoyagarwith5%
sheepblood.GBSwasidentiﬁedusingtheStrepTexlatexagglutinationsystem.GBSpositiveculturesweretestedfortheirresistance
to ampicillin, erythromycin, clindamycin, and cefazolin. GBS was isolated from 154 (12.2%) of 1264 swabs collected during the
study period. African-American women were more likely to be colonized with GBS than Caucasians and Hispanics. Resistance
to routinely administered antibiotics was common, but there were no statistically signiﬁcant increases in resistance to antibiotics
over the study period. Ongoing surveillance of antibiotic resistance patterns is important in determining optimal prophylaxis and
therapy.
Copyright © 2006 Lubna Chohan et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION
Despite a substantial decline in the incidence of early onset
group B Streptococcus (GBS) infections in the newborn, GBS
remains an important cause of morbidity and mortality in
thenewbornperiod.Clinicaltrialshavedemonstratedtheef-
fectiveness of antibiotic prophylaxis administered during la-
bor to women colonized with GBS in reducing disease in the
newborn [1–3]. Protocols that incorporate routine screen-
ing for group B Streptococcus with intrapartum chemopro-
phylaxis have recently been shown to prevent more cases of
early-onset disease than risk-based approaches [4].
One emerging threat to the current success of screening
and prophylaxis regimens is the emergence of antibiotic re-
sistance among group B Streptococcus strains. Penicillin G is
the antibiotic of choice for prophylaxis [5]. Other options
include ampicillin, and for penicillin-allergic patients, ce-
fazolin, clindamycin, erythromycin, or vancomycin. In sev-
eral studies, signiﬁcant resistance to clindamycin and ery-
thromycin has been identiﬁed [6–8].
Because of the importance of intrapartum antibiotics for
prevention of invasive GBS disease in the neonate and the
concern regarding emerging antibiotic resistance, the objec-
tives of this study were to determine GBS prevalence by eth-
nicity as well as GBS antibiotic resistance patterns in our
population.
SUBJECTS AND METHODS
Any pregnant woman (greater than 20 weeks gestation) who
presented to triage at Memorial Hermann Hospital (MHH)
or Lyndon Baines Johnson General Hospital (LBJ) was eli-
gible for the study. The study took place at three intervals
between 2001–2004. Each interval lasted approximately four
weeksinNovember2001,November2002,andJanuary2004.
Administrative approval for the study was obtained from the
institutional IRB and the IRB of both hospitals. All patients
were included without regard to race, parity, or previous an-
tibiotic use in pregnancy. In 2002 and 2004, additional infor-
mation was obtained regarding patient’s race and antibiotic
use during the current pregnancy. All women were ques-
tionedaboutpreviousvisitstotriageduringthestudyperiod,
a n dr e p e a ts u r v e i l l a n c ec u l t u r e sw e r en o tp e r f o r m e d .
In 2001, swabs were obtained from the vaginal sidewall.
In 2002 and 2004, swabs were taken from the vaginal side-
wall as well as anorectum. Transport swabs with liquid Stu-
art’s medium (Fisherbrand, Houston, Tex ) were plated onto
tryptic soy agar with 5% sheep blood (PML Microbiolog-
icals, Wilsonville, Ore) and inoculated into selective broth
(Lim broth, PML Microbiologicals, Wilsonville, Ore) and in-
cubatedfor18–24hours.Thebrothwassubculturedtoplates
of tryptic soy agar with 5% sheep blood (PML Microbi-
ologicals, Wilsonville, Ore). Colonies characteristic of GBS2 Infectious Diseases in Obstetrics and Gynecology
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Figure 1: GBS isolation rates stratiﬁed by ethnicity and year.
were identiﬁed using the StrepTex latex agglutination sys-
tem (Murex Biotech Limited, Kent, UK). To test for antimi-
crobial resistance, the disk diﬀu s i o nm e t h o d( B e c t o nD i c k -
inson, Sparks, Md) was used and the National Committee
for Clinical Laboratory Standards guidelines were used to
interpret the results. The antibiotics tested were: ampicillin
10µg, erythromycin 15µg, clindamycin 2µg, and cefazolin
30µg. Intermediate results were considered susceptible. Be-
cause zones of streptococcal growth inhibition to determine
resistance are not available for cefazolin, we used values for
Staphylococci.
All statistical calculations were performed with StataSE
8.2 (Stata Corp, College Station, Tex). Demographic charac-
teristics were compared with chi-square and logistic regres-
sion. Changes in the proportion of GBS isolation and the
proportion of resistant organisms over the study period were
comparedusingthenptrendtest(anonparametricextension
of the Wilcoxon rank-sum test). The odds of GBS coloniza-
tion were compared with logistic regression.
RESULTS
A total of 1264 patients were screened during this study. Of
these,301patients(24%)werescreenedin2001,446patients
(35%) in 2002, and 517 patients (41%) in 2004. Of the to-
tal 1264 patients, 989 (78%) were from LBJ and 275 (22%)
werefromMHH.ThemajorityofparticipantswereHispanic
(75%, 72%, resp, in 2002 and 2004), followed by African-
American (18%, 20%, resp), Caucasian (6%, 6%), and other
(1%, 2%).
Group B Streptococcus was found in 154 of 1264 (12.2%)
swabs. Of the 154 swabs, 20 were obtained in 2001, 67
were obtained in 2002, and 67 were obtained in 2004. The
proportion of women with GBS varied by ethnic back-
ground (Figure 1). African-American women were signiﬁ-
cantly more likely to be colonized with GBS (OR 1.9, 95%
CI 1.2, 2.9) than were non–African-American women.
Of the 154 GBS isolates, none were resistant to ampi-
cillin. Resistance to erythromycin was found in no isolates
in 2001, 10% (7 of 67) in 2002, and 9% (6 of 67) in 2004,
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Figure 2: Resistance to erythromycin among GBS isolates stratiﬁed
by year and location.
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Figure 3: Resistance to clindamycin among GBS isolates stratiﬁed
by year and location.
P = .41 (Figure 2). Resistance to clindamycin was found in
no isolates in 2001, 10% (7 of 67) in 2002, and 13% (9 of
67) in 2004, P = .38 (Figure 3). Using zone of inhibition
values for Staphylococci, resistance to cefazolin was found in
no isolates in 2001, 2% (1 of 67) in 2002, and 4% (3 of 67)
in 2004, P = .20. The prevalence of resistance among GBS
isolates was nearly twice as high among Caucasian women
(44%) compared to African-American (24%) or Hispanic
women(12%),P = .01(Figure 4).Theproportionofwomen
with GBS resistant to either clindamycin or erythromycin
increased from 0% to 15% to 19% across the study period
(P = .05).
We obtained antibiotic histories on our patients at the
time of screening for the last two years. We found that
226/924 (25%) of the women screened had taken antibiotics
during the pregnancy. The two most commonly used an-
tibiotics were nitrofurantoin (7%) and ﬂagyl (6%). Twenty-
one (3%) used two or more diﬀerent antibiotics. African-
American women were twice as likely to report antibioticLubna Chohan et al 3
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Figure 4: Antibiotic resistance stratiﬁed by ethnicity.
use during pregnancy (OR 2.4, 95% CI 1.7, 3.4). There was
no diﬀerence in the prevalence of group B Streptococcus iso-
lation among women who had taken antibiotics during the
pregnancy and those who had not (OR 1.1, 95% CI 0.7, 1.7).
Antibioticresistancewasnotsigniﬁcantlyrelatedtoexposure
to a particular antibiotic, but the sample sizes for these com-
parisons were small (data not shown).
DISCUSSION
In this study of 1264 anorectal and vaginal swabs with 154
GBS isolates in women presenting to labor and delivery, re-
sistance was found to antibiotics commonly used for GBS
p r o p h y l a x i sa sw e l la sf o rp r e m a t u r er u p t u r eo fm e m b r a n e s .
While antibiotic resistance varied by hospital and year, there
wasnostatisticallysigniﬁcantincreaseinantibioticresistance
over the study period.
Numerous other authors have evaluated the prevalence
of antibiotic resistance among group B Streptococcus over the
last15years[7–11].In1990,Berkowitzandcolleaguesevalu-
ated 156 GBS isolates and found uniform sensitivity to peni-
cillin and ampicillin and resistance to erythromycin, clin-
damycin, and cefoxitin in 3.2%, 2.5%, and 1.2% of strains,
respectively, [12]. Among rectovaginal samples, studies per-
formed more than 10 years later have found clindamycin re-
sistance ranging from 3%–21% and erythromycin resistance
ranging from 5%–29% [7–11, 13]. Among GBS isolates from
neonatal sepsis, erythromycin resistance was present in 8%
of strains, with 4.5% of these also resistant to clindamycin
[9]. Simoes and colleagues used a similar testing method to
evaluate the response of GBS to cefazolin and found 6%–8%
of GBS isolates were not considered sensitive [14].
We found that GBS carriage was more common in
African-American women, similar to previous reports [15,
16]. In Meyn’s study of 1248 nonpregnant women, African-
American race was associated with a higher prevalence of
GBS at screening and also with an increased rate of acquiring
vaginal GBS colonization [16]. This diﬀerential underscores
anopportunitytoimprovethedisparityinperinatalmorbid-
ity and mortality for African-Americans.
Manning and colleagues evaluated 117 group B Strepto-
coccusisolatesobtainedbetween8/1999and3/2000inMichi-
gan [17]. In their cohort, black ethnicity was associated with
resistance. In contrast, in our study, Caucasian ethnicity was
associatedwithcarriageofaresistantorganism.Thiswastrue
in spite of the fact that African-American women were more
likely to report antibiotic use during their pregnancy. In the
Manning study and in our own, the ethnic group with in-
creased carriage of resistant organisms had the smaller sam-
ple size. Further study with larger diverse populations, or
multicenter national sampling studies will be necessary to
determine the validity of the ethnic variations in carriage of
resistant organisms.
With more widespread use of antibiotics, selection of
antibiotic-resistant GBS may occur. If resistance continues
to be identiﬁed and increasing, changes in our current prac-
tices will need to occur. Current recommendations include
GBS susceptibility testing for clindamycin and erythromycin
in penicillin-allergic patients [5]. Identiﬁcation of factors as-
sociatedwithcolonizationandparticularlycolonizationwith
resistant organisms is important in maintaining the success
of current programs to reduce perinatal morbidity and mor-
tality from invasive GBS disease. Ongoing surveillance of an-
tibioticresistancepatternsinbothpregnantwomenandtheir
infantswillbeimportantindeterminingoptimalprophylaxis
and therapy for our patients.
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